cytotoxic T cell

Overview

Cytotoxic T cells, also known as CD8+ T cells, are a subtype of T lymphocytes that play a crucial role in the immune response by directly killing infected or cancerous cells. They recognize and eliminate cells presenting specific antigens through the T-cell receptor (TCR) and are essential for controlling viral infections and tumor growth. Upon activation, cytotoxic T cells proliferate and differentiate into effector cells capable of releasing cytotoxic granules containing perforin and granzymes, which induce apoptosis in target cells. Their functionality is modulated by various factors, including cytokines such as interferon-gamma (IFNG) and interactions with immune checkpoint proteins like PD-1 and CTLA-4.

Focus of Latest Publications

Recent studies have highlighted the pivotal role of cytotoxic T cells in cancer immunotherapy and the tumor microenvironment. For instance, a phase II trial combining pembrolizumab, a PD-1 inhibitor, with paclitaxel and carboplatin in melanoma demonstrated that an objective response was associated with a higher proportion of mature NK cells and CD4 T cells expressing BTLA or LAIR-1, alongside a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline (PMID: 41732954). This underscores the importance of T cell maturation and the immune landscape in therapeutic outcomes.

In another study, the use of splenic dendritic cell-targeting mRNA transfection significantly increased the amounts of IFN-γ+ CD8+ T cells and effector memory CD8+ T cells, suggesting that enhancing antigen presentation can boost cytotoxic T cell responses (PMID: 41737632). Similarly, the combination of L19-TNF with a CD3-based bispecific T-cell engager (TCE) was shown to enhance tumor cell killing and CD8+ T-cell proliferation, indicating that Targeted therapies can synergistically improve T cell-mediated tumor destruction (PMID: 42012522).

Moreover, research has explored the mechanisms of immune evasion in tumors, such as the orchestration of IL-33-mediated M2-like polarization of tumor-associated macrophages, which was linked to reduced infiltration of CD8+ T cells in colorectal cancer models (PMID: 41962054). This highlights the complex interplay between tumor microenvironment factors and cytotoxic T cell activity.

Innovative therapeutic strategies, including the use of biomimetic nanodecoys and programmable DNAzyme nanocatalysts, have been developed to enhance cytotoxic T cell infiltration and activation in tumors (PMID: 42002768; PMID: 41981590). These approaches aim to remodel the immune microenvironment and improve the efficacy of existing immunotherapies, such as checkpoint inhibitors.

Additionally, studies have indicated that androgen receptor signaling can induce CD8+ T-cell dysfunction, which can be reversed by androgen deprivation therapy, further emphasizing the importance of understanding the regulatory mechanisms affecting cytotoxic T cell function in various cancer types (PMID: 41661680).

Key Publications

• Jun Multi-omics identifies VMP1 as a tumor-intrinsic biomarker associated with metastatic progression and immune microenvironment remodeling in HNSCC. (Translational oncology, 2026, PMID 42314513): "...was also associated with decreased CD8+ T-cell infiltration and impaired effector features."
• Jun Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot. (Cancer immunology research, 2026, PMID 42012522): "In vitro, L19-TNF in combination with a CEAxCD3 TCE significantly enhanced tumor cell killing and CD8+ T-cell proliferation."
• Jun A pH-responsive polymeric nanovaccine with efficient endosomal escape and potent antitumor immunity for cancer treatment. (Acta biomaterialia, 2026, PMID 41966320): "These result in greatly enhanced antigen cross-presentation and dendritic cell maturation, which together drive strong activation and effector differentiation of antigen-specific CD8⁺ T cells."
• May Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming. (Signal transduction and targeted therapy, 2026, PMID 42091852): "TNF-α neutrophils enhanced CD8+ T-cell function via ICAM-1-LFA-1 interactions, and adoptive transfer confirmed their intrinsic antitumor activity in vivo."
• May Bioorthogonal Cu-MOF nanocatalyst enables GSH-triggered in situ drug synthesis for xCT-driven ferroptosis in colorectal cancer. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41780681): "In vivo, HMOI treatment increased CD8+ T-cell infiltration and IFN-γ production, reflecting enhanced antitumor immune activity alongside ferroptotic pressure."
• May Lipophilic Statins Deplete GPX4 to Promote Ferroptosis and Sensitize Cancer Cells to Immune Checkpoint Blockade. (Molecular cancer therapeutics, 2026, PMID 41423587): "lower expression of mevalonate pathway genes correlates with increased CD8+ T-cell infiltration and improved overall survival in patients with melanoma."
• May Androgen Receptor Signaling Induces CD8+ T-cell Dysfunction That Is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma. (Cancer research, 2026, PMID 41661680): "identified androgen receptor (AR) signaling as a key regulator of the tumor immune microenvironment by modulating CD8+ T-cell differentiation and function."
• Apr Biomimetic nanodecoys remodel the mechano-immune microenvironment to potentiate checkpoint blockade in colorectal cancer. (Journal of nanobiotechnology, 2026, PMID 42002768): "This alleviation of the mechanical niche is associated with enhanced cytotoxic T cell infiltration, which synergizes with co-delivered PD-L1 antibodies to activate antitumor immunity."
• Apr Faecalibacterium prausnitzii enzyme reprograms PD-L1 trafficking and sensitizes colorectal cancer to immunotherapy in mice. (Nature microbiology, 2026, PMID 41998161): "Mass spectrometry identifies F. prausnitzii phosphoribosyl pyrophosphate synthetase (fpPRPS) as a bacterial enzyme that inhibits tumour development and promotes CD8+ T-cell responses."
• Apr Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. (Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026, PMID 41995149): "These effects were augmented by immune activation, including increased CD8+T-cell infiltration, reduced regulatory T cells, and M2-like macrophage population."